Becton, Dickinson and Company (NYSE:BDX) Stock Gets Price Target Boost from Citigroup

06 Nov 2026, 21:48 by Sarita Garza · The Markets Daily

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) had its price objective hoisted by equities researchers at Citigroup from $208.00 to $241.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s target price indicates a potential upside of 13.53% from the company’s previous close.

A number of other equities research analysts also recently weighed in on BDX. Stifel Nicolaus set a $195.00 price target on shares of Becton, Dickinson and Company in a report on Friday, August 7th. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price on the stock. Bank of America increased their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Zacks Research upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. Finally, Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $193.67.

View Our Latest Stock Analysis on BDX

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $1.28 during trading on Friday, hitting $212.27. The stock had a trading volume of 2,118,168 shares, compared to its average volume of 2,434,846. The business has a fifty day moving average of $187.69 and a two-hundred day moving average of $170.23. Becton, Dickinson and Company has a fifty-two week low of $137.35 and a fifty-two week high of $214.88. The firm has a market cap of $58.49 billion, a P/E ratio of 63.94, a PEG ratio of 14.10 and a beta of 0.22. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.96 earnings per share. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a share buyback program on Thursday, November 5th that authorizes the company to buy back 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Share repurchase programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 6,907 shares of company stock worth $1,269,128. Company insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDX. TD Waterhouse Canada Inc. lifted its holdings in shares of Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after purchasing an additional 14,077 shares in the last quarter. Northside Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after buying an additional 9,494 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Becton, Dickinson and Company by 35.0% during the first quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after buying an additional 11,414 shares in the last quarter. Capital Analysts LLC raised its position in Becton, Dickinson and Company by 7.5% during the second quarter. Capital Analysts LLC now owns 83,601 shares of the medical instruments supplier’s stock valued at $12,651,000 after buying an additional 5,828 shares during the period. Finally, Beverly Hills Private Wealth LLC acquired a new position in Becton, Dickinson and Company during the second quarter valued at $3,353,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Trending Headlines about Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

Positive Sentiment: BD beat Q4 estimates, reporting adjusted EPS of $4.15 versus about $4.07 expected and revenue of $5.27 billion versus $5.11 billion expected. Revenue rose 5.4% year over year; full-year free cash flow increased 42.5% to $2.9 billion. BD fiscal 2026 results
Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares—about 3.6% of shares outstanding. These actions may support shareholder returns. Dividend and buyback announcement
Neutral Sentiment: Analysts raised price targets: RBC to $225 while maintaining a sector-perform rating, Piper Sandler to $200 with a neutral rating, and Evercore ISI to $230. The targets are mixed relative to BDX’s recent trading level and do not signal a clear consensus shift. Piper Sandler target update
Negative Sentiment: Despite the quarterly beat, BDX’s fiscal 2027 revenue-growth outlook was described as subdued and full-year guidance came in slightly below expectations. Investors may be focused on the prospect of slower growth, which helps explain pressure on the shares after results. BD outlook coverage

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.